Bifogade filer
Q2, 2021, MagleChemoswedHolding
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The second quarter of 2021 is in line with forecast with strong demand in the CDMO services and manufacturing.
“The second quarter continued to show recovery to pre-COVID business levels, and we have started seeing growth in the CDMO segment as customers clinical programs are rescheduled and planned. Once again, I have been impressed by our high working capacity helping us meet our customer’s needs. Our technology product pipeline continues to grow as we have planned and expected” said Justin Pierce, Magle Chemoswed Holding’s CEO.
- Net sales amounted to 33,5 MSEK (34,2).
- EBITDA equalled 4 MSEK (6,7).
- Operating profit (EBIT) is 1,2 MSEK (3,0)
- Profit after tax amounted to 0,75 MSEK (2,5)
- Earnings per share amounted to SEK 0,07 (0,25) per share
*A share split was carried out on the 27th of March 2020 and a share issue was carried out on the 4th of January 2021. These actions have an effect on the earnigns per share over the comparative periods.
The financial report is published on the Company website and can be accessed via this link https://maglechemoswed.com/financial-information/.
The second quarter results are presented as unaudited accounts for the period and have not been audited by the Company auditors.
The next financial report is scheduled according to the Financial Calendar and will be the third quarter interim report and will be reported at 07:00 on November 16, 2021.